NYSE:PFE

Stock Analysis Report

Executive Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.


Snowflake Analysis

Outstanding track record 6 star dividend payer.


Similar Companies

Share Price & News

How has Pfizer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PFE has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.2%

PFE

-0.5%

US Pharmaceuticals

-1.1%

US Market


1 Year Return

-16.9%

PFE

6.2%

US Pharmaceuticals

17.9%

US Market

Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: PFE underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

PFEIndustryMarket
7 Day-2.2%-0.5%-1.1%
30 Day-10.3%-1.0%1.4%
90 Day-7.7%5.7%6.9%
1 Year-13.6%-16.9%8.9%6.2%20.3%17.9%
3 Year16.4%4.3%25.4%16.6%47.8%38.3%
5 Year24.8%4.1%29.7%15.7%71.9%53.0%

Price Volatility Vs. Market

How volatile is Pfizer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pfizer undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PFE ($35.72) is trading below our estimate of fair value ($82.32)

Significantly Below Fair Value: PFE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PFE is good value based on its PE Ratio (12.2x) compared to the Pharmaceuticals industry average (21.6x).

PE vs Market: PFE is good value based on its PE Ratio (12.2x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: PFE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PFE is good value based on its PB Ratio (3x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

-5.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PFE's earnings are forecast to decline over the next 3 years (-5.6% per year).

Earnings vs Market: PFE's earnings are forecast to decline over the next 3 years (-5.6% per year).

High Growth Earnings: PFE's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PFE's revenue (1.5% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: PFE's revenue (1.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (26.1%)


Next Steps

Past Performance

How has Pfizer performed over the past 5 years?

18.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PFE has high quality earnings.

Growing Profit Margin: PFE's current net profit margins (31.4%) are higher than last year (20.8%).


Past Earnings Growth Analysis

Earnings Trend: PFE's earnings have grown by 18.6% per year over the past 5 years.

Accelerating Growth: PFE's earnings growth over the past year (46%) exceeds its 5-year average (18.6% per year).

Earnings vs Industry: PFE earnings growth over the past year (46%) exceeded the Pharmaceuticals industry 2.4%.


Return on Equity

High ROE: PFE's Return on Equity (24.9%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Pfizer's financial position?


Financial Position Analysis

Short Term Liabilities: PFE's short term assets ($33.5B) do not cover its short term liabilities ($37.0B).

Long Term Liabilities: PFE's short term assets ($33.5B) do not cover its long term liabilities ($68.1B).


Debt to Equity History and Analysis

Debt Level: PFE's debt to equity ratio (80.5%) is considered high.

Reducing Debt: PFE's debt to equity ratio has increased from 51.3% to 80.5% over the past 5 years.

Debt Coverage: PFE's debt is well covered by operating cash flow (25.7%).

Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (13.3x coverage).


Balance Sheet

Inventory Level: PFE has a low level of unsold assets or inventory.

Debt Coverage by Assets: PFE's debt is not covered by short term assets (assets are 0.6x debt).


Next Steps

Dividend

What is Pfizer's current dividend yield, its reliability and sustainability?

4.26%

Current Dividend Yield


Dividend Yield vs Market

company4.3%marketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Years4.4%

Current dividend yield vs market & industry

Notable Dividend: PFE's dividend (4.26%) is higher than the bottom 25% of dividend payers in the US market (1.45%).

High Dividend: PFE's dividend (4.26%) is in the top 25% of dividend payers in the US market (3.73%)


Stability and Growth of Payments

Stable Dividend: PFE's dividends per share have been stable in the past 10 years.

Growing Dividend: PFE's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (49.3%), PFE's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PFE's dividends in 3 years are forecast to be covered by earnings (50.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average management tenure


CEO

Albert Bourla (57yo)

1.1yrs

Tenure

US$9,854,557

Compensation

Mr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Mr. Bourla was Chief Operating Officer  ...


CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD9.85M) is about average for companies of similar size in the US market ($USD10.81M).

Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Albert Bourla
Chairman of the Board & CEO1.1yrsUS$9.85m0.0051% $10.1m
John Young
Group President & Chief Business Officer7.7yrsUS$7.12m0.0065% $12.9m
Frank D'Amelio
CFO & EVP of Global Supply & Business Operations12.4yrsUS$7.14m0.0061% $12.1m
Mikael Dolsten
Chief Scientific Officer and President of Worldwide Research0.6yrsUS$7.07mno data
Loretta Cangialosi
Senior VP0yrsno data0.0020% $4.0m
Lidia Fonseca
Executive VP and Chief Digital & Technology Officer1.1yrsno data0.00078% $1.5m
Charles Triano
Senior Vice President of Investor Relations11.7yrsno datano data
Douglas Lankler
Executive VP & General Counsel6.2yrsno data0.0019% $3.7m
Rady Johnson
Executive VP and Chief Compliance6.2yrsno data0.0012% $2.3m
Alexander MacKenzie
Executive VP & Chief Development Officer3.9yrsno data0.0016% $3.2m

6.2yrs

Average Tenure

57yo

Average Age

Experienced Management: PFE's management team is seasoned and experienced (6.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Albert Bourla
Chairman of the Board & CEO1.1yrsUS$9.85m0.0051% $10.1m
W. Cornwell
Independent Director23yrsUS$368.75kno data
Shantanu Narayen
Lead Independent Director2.1yrsUS$382.32kno data
Ronald Blaylock
Independent Director3yrsUS$363.39kno data
James Kilts
Independent Director12.4yrsUS$345.89k0.000040% $79.1k
Suzanne Nora Johnson
Independent Director12.4yrsUS$363.39k0.00018% $355.8k
James Smith
Independent Director5.7yrsUS$363.39k0.000060% $118.6k
Charles Hagel
Member of Emerging Markets Advisory Board0yrsno datano data
Joseph Echevarria
Independent Director4.7yrsUS$353.75kno data
Helen Hobbs
Independent Director8.2yrsUS$378.39kno data

5.7yrs

Average Tenure

62yo

Average Age

Experienced Board: PFE's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PFE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pfizer Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pfizer Inc.
  • Ticker: PFE
  • Exchange: NYSE
  • Founded: 1849
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$197.679b
  • Shares outstanding: 5.53b
  • Website: https://www.pfizer.com

Number of Employees


Location

  • Pfizer Inc.
  • 235 East 42nd Street
  • New York
  • New York
  • 10017
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PFENYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
PFE *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
0Q1NLSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
PFEOM (OMX Nordic Exchange Stockholm)YesCommon StockSESEKJan 1968
PFEDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
PFEXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1968
PFEBVC (Bolsa de Valores de Colombia)YesCommon StockCOCOPJan 1968
PFESBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBSEKJan 1968
PFESNSE (Santiago Stock Exchange)YesCommon StockCLUSDJan 1968
PF-UETLX (Eurotlx)YesCommon StockITEURJan 1968
PFEWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1968
PFEBVL (Bolsa de Valores de Lima)YesCommon StockPEUSDJan 1968
US_PFE_KAS (Kazakhstan Stock Exchange)YesCommon StockKZKZTJan 1968
PFEBASE (Buenos Aires Stock Exchange)CEDEAR EACH 2 REP 1 ORD USD0.05ARARSSep 2000
PFIZ34BOVESPA (Bolsa de Valores de Sao Paulo)BDR REPR 1 COM STK NPVBRBRLMay 2011

Biography

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, Merck KGaA, Nektar Therapeutics, Syapse, Inc., eFFECTOR Therapeutics, Inc., and Insilico Medicine, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 01:09
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.